Abiopharma

🔍 Blumer Brendan Francis (Executive)

Company: Bullish (BLSH)

Report Date: 2026-04-02

Detailed Transactions and Holdings:

• Holds 0 shares of Ordinary Shares (Direct)
  Date: 2026-04-02 | Code: H | shares_owned_after: 39,157,869.00
• Holds 0 shares of Ordinary Shares (Direct)
  Date: 2026-04-02 | Code: H | shares_owned_after: 4,139.00 | Footnotes: F1
• Sold 7,813 shares of Call Option (obligation to sell) at $11.1 per share (Derivative)
  Date: 2026-04-02 | Code: X | Expires: 2026-04-02 | Exercise: 2026-04-02 | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F2, F2

Footnotes:

• F1: Represents 4,139 restricted share units ("RSUs") granted to the Reporting Person on November 6, 2025, pursuant to the Bullish 2025 Omnibus Incentive Plan. The RSUs vest in full on September 1, 2026.
• F2: Represents the exercise and settlement of the remaining 7,813 shares subject to a previously disclosed call option agreement, as amended and modified from time to time, between Buttonwood Investments I ("Buttonwood") and the optionholders thereto. Buttonwood is an exempted company domiciled in the Cayman Islands with limited liability. Brendan Blumer (the "Reporting Person") holds 100% of the outstanding equity interests in Buttonwood and is a director of Buttonwood. The Reporting Person disclaims beneficial ownership of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is or was the beneficial owner of such securities for purposes of Section 16 of the Exchange Act or for any other purpose
• REMARKS: Due to the issuer's status as a foreign private issuer pursuant to Rule 3a12-3(b) under the Exchange Act, the reporting person's transactions in the issuer's equity securities are exempt from Sections 16(b) and 16(c) of the Exchange Act.